1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Daewoong Co., Ltd.

Daewoong Co., Ltd.

003090.KS
Daewoong Co., Ltd.KR flagKorea Exchange
17,030.00
KRW
- -
- -
715.89BMarket Cap
Daewoong Co., Ltd.
003090.KS
(Korea Exchange)

Recent

price

17,030.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
15,926.39
6,424.79
19,447.86
19,927.87
20,979.84
23,392.7
23,556.55
26,027.41
28,529.1
31,625.01
32,278.83
36,378.08
40,825.92
43,865.31
47,381.02
50,568.26
50,433.39
Revenue per Share
768.35
1,027.15
1,051.05
963.2
558.8
906.6
460.26
1,534
692
1,424
2,343
1,895
2,467
3,692
1,416
4,280
4,466.06
Basic EPS, GAAP
-959.77
-514.98
691.2
1,425.29
-344.94
-1,068.01
-3,603.99
1,035.43
-502.74
1,624.28
1,911.98
425.23
756.68
-563.53
-4,254.48
-2,209.53
-2,942.79
Free Cash Flow per Basic Share
205.24
81.55
223.72
212.25
205.15
192.05
189.89
177.79
177.95
177.83
182.03
180.03
214.2
196.35
200.46
308.5
52.11
Dividend per Share
3,953.07
5,301.67
5,777.64
6,563.24
6,841.72
8,218.05
8,470.19
9,893.32
10,348.78
11,524.01
14,320.52
16,229.8
18,620.48
22,301.18
23,856.69
27,825.95
28,270.12
Book Value per Share
11,579.19
7,810.89
13,549.66
15,153.64
15,693.89
16,087.74
16,367.92
17,576.86
18,742.21
19,532.04
22,174.19
22,166.82
24,154.92
27,310.23
28,049.17
33,918.73
35,261.02
Tangible Book Value per Share
42
42
42
42
43
43
43
43
43
43
42
42
42
41
41
41
41
Basic Weighted Avg Shares
670,825
270,641
819,232
843,534
893,977
996,587
1,014,966
1,124,076
1,231,174
1,365,679
1,355,337
1,511,374
1,697,338
1,813,841
1,936,917
2,068,370
2,079,643
Sales/Revenue/Turnover
13.45
9.92
8.47
11.55
8.8
7.98
6.01
7.53
7.24
7.79
7.23
12.07
12.22
10.78
14.55
12.66
11.95
Operating Margin (%)
15,712
10,475
30,688
30,252
30,143
36,760
38,785
50,216
59,062
49,881
50,849
50,558
48,279
54,221
58,785
62,885
67,540
Depreciation Expense
32,363
43,268
44,275
40,772
23,811
38,623
19,831
66,251
29,863
61,493
98,379
78,730
102,566
152,665
57,886
175,063
184,160
Net Income, GAAP
28.97
10.29
16.03
22.66
43.45
32.04
39.51
- -
46.14
12.1
18.14
11.86
22.37
5.47
40.52
6.45
7.59
Effective Tax Rate (%)
4.82
15.99
5.4
4.83
2.66
3.88
1.95
5.89
2.43
4.5
7.26
5.21
6.04
8.42
2.99
8.46
8.86
Profit Margin (%)
177,487
31,378
205,631
297,994
411,648
436,190
433,398
437,884
351,705
462,864
468,576
329,534
438,249
143,125
237,584
262,631
182,020
Working Capital
41,935
11,062
3,195
40,066
139,512
189,410
289,165
289,336
179,686
292,811
295,697
188,361
210,315
67,083
326,721
552,476
552,395
LT Debt
484,696
336,102
620,031
687,068
708,732
828,479
864,632
939,306
964,313
1,016,135
1,116,918
1,152,542
1,279,496
1,436,799
1,502,496
1,767,326
1,853,064
Total Equity
11.07
4.82
10.78
10.31
5.38
5.5
3.12
- -
3.55
6.73
5.37
10.1
9.66
10.22
8.24
10.15
9.2
Return on Invested Capital (%)
0.79
11.04
6.01
1.39
1.6
2.98
0.77
- -
2.64
4.88
6.29
4.42
5.68
7.18
2.55
5.67
5.21
Return on Capital (%)
21.28
22.2
18.97
15.65
8.36
12.04
5.55
16.73
6.83
13.02
17.9
12.34
14.16
18
6.1
16.57
17.05
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
358,669
325,739
396,058
LT Borrowings
481,508
550,577
550,831
LT Finance Leases
2,063
1,899
1,564
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
41
42
42
Market Capitalization
897,458
901,547
960,786

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
1,126,152
1,032,400
1,078,816
Cash, Cash Equivalents & STI
346,124
285,795
301,490
Accounts Receivable, Net
210,893
203,760
210,622
Inventories
455,141
444,556
461,510
Total Current Liabilities
784,118
769,770
896,796
Payables & Accruals
- -
- -
- -
ST Debt
358,669
325,739
396,058
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.96%
9.74%
17.63%
Free Cash Flow
-2.05%
84.87%
-48.04%
Net Income, GAAP
49.59%
39.9%
202.43%
Sales/Revenue/Turnover
7.65%
8.85%
6.79%
Total Cash Common Dividend
- -
12.6%
53.98%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
443,861
473,290
515,875
503,891
1,936,917
2025
481,435
528,428
542,175
516,332
2,068,370
2026
492,707
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
516
489
1,088
- -
1,416
2025
640
950.92
981.49
- -
4,280
2026
841
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
10.94
- -
200.46
2025
- -
- -
28.43
- -
308.5
2026
23.32
- -
- -
- -
- -
Similar Companies
Sanofi (SNW.DE)
Grifols, S.A. (GRFS)
Cipla Limited (CIPLA.NS)
Pfizer Inc. (PFE.BA)
Eli Lilly and Company (LLY.SW)
Virbac S.A. (VIRP.PA)
Business
Daewoong Co., Ltd. engages primarily in the research, development, manufacturing, and sale of pharmaceutical products, serving both domestic and international markets. The company's product portfolio includes biologics, chemical pharmaceuticals, new drugs, biosimilars, stem cell therapies, antibiotics, enzymes, medical devices, and finished dosage forms. Daewoong markets specialty and generic pharmaceuticals across therapeutic areas including chronic, autoimmune, and orphan diseases. The company also provides contract manufacturing organization (CMO) services and operates a division for real estate rental and lifestyle-related disease prevention research. Headquartered in Seongnam, South Korea, Daewoong was founded in 1945 and has expanded its global footprint with branch offices and research centers in the United States, China, India, and throughout Asia. In recent developments over the last 1-2 years, Daewoong has significantly enhanced its strategic partnerships and research collaborations globally. Notably, it entered a research collaboration with Swedish biotech firm Salipro Biotech in 2025 to advance novel therapeutics using Salipro’s proprietary technology. It strengthened its strategic partnership with M8 Pharmaceuticals to commercialize diabetes treatment Envlo™ in Latin America. Daewoong has been expanding its product offerings in the aesthetic medicine sector through launching Total K-Aesthetic Solutions in markets like Indonesia, integrating botulinum toxins, hyaluronic acid fillers, and thread lifting products. Additionally, Daewoong Bio opened a Bio-Center in South Korea to provide integrated CMO services, reinforcing the company’s contract manufacturing capabilities. These moves complement Daewoong’s ongoing emphasis on innovative new drug development, global expansion, and enhanced manufacturing capacity under cGMP guidelines. Daewoong operates mainly within the pharmaceutical and healthcare industry segments, targeting healthcare providers, hospitals, and pharmaceutical distributors across Asia, the Americas, and other international markets. It offers a comprehensive range of pharmaceutical products under its own brands and through partnerships, supported by strong in-house R&D and advanced global collaborations. The company remains focused on delivering innovative treatments for unmet medical needs while growing its presence in biopharmaceuticals and aesthetic medicine on a global scale. In summary, Daewoong Co., Ltd. is a leading South Korean pharmaceutical company specializing in pharmaceuticals, biologics, biosimilars, stem cell therapies, medical devices, and contract manufacturing services. With a strong emphasis on new drug development and global partnerships, the company has recently expanded into novel therapeutic platforms, Latin American markets, and aesthetic solutions, reinforcing its position as a global healthcare enterprise. It was founded in 1945 and is headquartered in Seongnam, South Korea.